Biotech News

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

GENFIT (GNFT)GENFIT2026-05-21 16:00 ESTEarnings

Cash and cash equivalents totaled €136.1 million as of March 31, 2026 €9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor) Positive momentum across all growth platforms, combining increased revenue visibility and upside optionality: An

GENFIT

Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s...

Recent company news

GNFTGENFIT2026-08-03 14:32 EST

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GNFTGENFIT2026-07-08 16:00 EST

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GNFTGENFIT2026-07-02 16:05 EST

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GNFTGENFIT2026-06-23 16:00 EST

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States